Go Pro
→ Trump and Bernie agree on this (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$8.61
+2.0%		$10.62
$2.37
▼
$14.53
$420.94M2.18292,684 shs2.21 million shs
KARD
Kardigan
$16.64
-0.3%		$20.61
$15.86
▼
$27.00
$1.56BN/A382,854 shs6.57 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.83
+8.2%		$3.26
$2.77
▼
$7.18
$2.05B1.0714.79 million shs44.22 million shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$5.02
-2.7%		$5.79
$2.71
▼
$7.30
$1.64B1.192.55 million shs9.12 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
0.00%-15.75%-22.71%-12.32%+277.63%
KARD
Kardigan
0.00%-10.15%-17.87%-24.36%+1,663,999,900.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+19.69%+14.67%+18.58%-18.68%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%0.00%-17.84%-21.81%+73.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$8.61
+2.0%		$10.62
$2.37
▼
$14.53
$420.94M2.18292,684 shs2.21 million shs
KARD
Kardigan
$16.64
-0.3%		$20.61
$15.86
▼
$27.00
$1.56BN/A382,854 shs6.57 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.83
+8.2%		$3.26
$2.77
▼
$7.18
$2.05B1.0714.79 million shs44.22 million shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$5.02
-2.7%		$5.79
$2.71
▼
$7.30
$1.64B1.192.55 million shs9.12 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
0.00%-15.75%-22.71%-12.32%+277.63%
KARD
Kardigan
0.00%-10.15%-17.87%-24.36%+1,663,999,900.00%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+19.69%+14.67%+18.58%-18.68%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%0.00%-17.84%-21.81%+73.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.83
Moderate Buy$39.00352.96% Upside
KARD
Kardigan
2.50
Moderate Buy$42.25153.91% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.06110.44% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$12.77154.37% Upside

Current Analyst Ratings Breakdown

Latest ARTV, KARD, RXRX, and TSHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/14/2026
KARD
Kardigan
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D)
8/25/2026
KARD
Kardigan
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$51.00 ➝ $46.00
8/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.30
7/21/2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/21/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$11.00 ➝ $13.00
7/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
KARD
Kardigan
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/13/2026
KARD
Kardigan
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$46.00
7/13/2026
KARD
Kardigan
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
7/13/2026
KARD
Kardigan
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$46.00
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K1,683.77N/AN/A$4.48 per share1.92
KARD
Kardigan
N/AN/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M27.46N/AN/A$2.14 per share1.79
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$9.77M167.42N/AN/A$0.90 per share5.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$83.86M-$3.30N/AN/AN/AN/A-53.86%-48.16%11/11/2026 (Estimated)
KARD
Kardigan
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$109M-$0.42N/AN/AN/AN/A-56.19%-41.84%11/3/2026 (Estimated)

Latest ARTV, KARD, RXRX, and TSHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
KARD
Kardigan
N/A-$4.61N/A-$4.61N/AN/A
8/11/2026Q2 2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.1133-$0.13-$0.0167-$0.13$0.68 millionN/A
8/6/2026Q2 2026
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.6251-$0.63-$0.0049-$0.63N/AN/A
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
KARD
Kardigan
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
24.16
24.16
KARD
Kardigan
N/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.13
17.76
17.76

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
KARD
Kardigan
N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
1.80%
KARD
Kardigan
N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
11548.89 million48.01 millionN/A
KARD
Kardigan
24193.50 millionN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
600535.34 million499.74 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
99325.83 million314.50 millionOptionable

Recent News About These Companies

Wolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)
September 19 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031948
Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research
September 17 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-taysha-gene-therapies-nasdaq-tsha-earns-outperform-rating-from-analysts-at-wolfe-research-2026-09-17/
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts
September 17 at 3:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31028759
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-taysha-gene-therapies-inc-nasdaq-tsha-receives-average-recommendation-of-buy-from-analysts-2026-09-12/
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945540-taysha-gene-therapies-a-bull-case-that-does-not-require-the-fastest-approval
Illustration of an industrial facility with a glowing upward arrow chart line overlaid against a city skyline at dusk.
These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)
...
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/these-3-risky-stocks-could-be-sitting-on-100-upside/
Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-acquires-3349244-shares-of-taysha-gene-therapies-inc-tsha-2026-09-06/
Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-new-position-in-taysha-gene-therapies-inc-tsha-2026-09-06/
Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-has-994-million-holdings-in-taysha-gene-therapies-inc-tsha-2026-09-05/
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356521/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-750-million-stake-in-taysha-gene-therapies-inc-tsha-2026-08-26/
Taysha Gene Therapies Earnings Call Highlights Pivotal Progress
August 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/taysha-gene-therapies-earnings-call-highlights-pivotal-progress?utm_source=marketbeat.com&utm_medium=referral
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-q2-231331648.html
Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TSHA/pressreleases/3824580/wells-fargo-issues-a-buy-rating-on-taysha-gene-therapies-tsha/
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-tsha-rett-140937044.html
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69283092-taysha-gene-therapies-inc-taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/taysha-gene-therapies-inc-tsha-050217398.html
Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4631192-taysha-outlines-reveal-6-month-interim-analysis-and-fda-feedback-in-h1-2027-while-targeting
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935110-taysha-gene-therapies-inc-tsha-q2-2026-earnings-call-transcript
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343130/0/en/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338769/0/en/taysha-gene-therapies-to-release-second-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-august-11.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Hewlett Packard Enterprise logo displayed in a data center aisle lined with illuminated server racks.
Why Hewlett Packard Enterprise’s Sell-Off May Not Last
By Thomas Hughes | September 6, 2026
Hewlett Packard Enterprise logo and name displayed on a wall beside a server data center corridor.
How 4 Million Hewlett Packard Shares Bought an AI Network
By Jeffrey Neal Johnson | September 7, 2026
Broadcom logo displayed above a computer chip on a circuit board, with a server room corridor in the background.
Enterprise AI to Boost Broadcom's Software Business? What Industry Data Shows
By Leo Miller | September 17, 2026
Rows of server racks with illuminated blue lights in a data center, with a city skyline visible through windows.
5 Names That Showed Signs of Life After Friday's CPI Report
By Ryan Hasson | September 14, 2026
Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$8.61 +0.17 (+2.01%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$8.65 +0.04 (+0.49%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Kardigan NASDAQ:KARD

$16.64 -0.05 (-0.30%)
As of 09/18/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.83 +0.29 (+8.19%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.80 -0.04 (-0.91%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$5.02 -0.14 (-2.71%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.02 0.00 (0.00%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas